News
BCTX
4.315
+0.82%
0.035
Weekly Report: what happened at BCTX last week (0914-0918)?
Weekly Report · 6d ago
BriaCell announces DSMB recommendation to continue Bria-ABC study
TipRanks · 09/14 11:35
Weekly Report: what happened at BCTX last week (0907-0911)?
Weekly Report · 09/14 09:07
Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Benzinga · 09/08 11:35
Weekly Report: what happened at BCTX last week (0831-0904)?
Weekly Report · 09/07 09:06
Weekly Report: what happened at BCTX last week (0824-0828)?
Weekly Report · 08/31 09:07
BriaCell Advances Off-the-Shelf Personalized Melanoma Vaccine Toward Clinic
TipRanks · 08/24 12:11
BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
Benzinga · 08/24 11:33
Weekly Report: what happened at BCTX last week (0817-0821)?
Weekly Report · 08/24 09:07
Weekly Report: what happened at BCTX last week (0810-0814)?
Weekly Report · 08/17 09:07
Weekly Report: what happened at BCTX last week (0803-0807)?
Weekly Report · 08/10 09:06
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
Benzinga · 08/05 11:33
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
Barchart · 08/05 06:30
Weekly Report: what happened at BCTX last week (0727-0731)?
Weekly Report · 08/03 09:06
Weekly Report: what happened at BCTX last week (0720-0724)?
Weekly Report · 07/27 09:07
Weekly Report: what happened at BCTX last week (0713-0717)?
Weekly Report · 07/20 09:06
Source Rock Royalties Declares Monthly Dividend and Grants New RSUs
TipRanks · 07/16 11:51
BriaCell announces Odette Cancer Centre joins Bria-IMT trial
TipRanks · 07/16 11:40
Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Benzinga · 07/16 11:36
Stocks in play: BriaCell Therapeutics Corp.
Barchart · 07/16 08:53
More
Webull provides a variety of real-time BCTX stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.